Drug discovery and p53
- 1 April 2003
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 8 (8), 347-355
- https://doi.org/10.1016/s1359-6446(03)02669-2
Abstract
No abstract availableThis publication has 65 references indexed in Scilit:
- p53 latency – out of the blind alleyTrends in Biochemical Sciences, 2002
- Highly potent p21WAF1‐derived peptide inhibitors of CDK‐mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin AChemical Biology & Drug Design, 2002
- Recognition of DNA by p53 Core Domain and Location of Intermolecular Contacts of Cooperative BindingJournal of Molecular Biology, 2002
- Hsp90 as a capacitor of phenotypic variationNature, 2002
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002
- p53 Latency: C-TERMINAL DOMAIN PREVENTS BINDING OF p53 CORE TO TARGET BUT NOT TO NONSPECIFIC DNA SEQUENCESPublished by Elsevier BV ,2001
- Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathwaysOncogene, 2000
- Pharmacological Rescue of Mutant p53 Conformation and FunctionScience, 1999
- Intrinsically unstructured proteins: re-assessing the protein structure-function paradigmJournal of Molecular Biology, 1999
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994